NLRP3 and colorectal carcinoma: Although GSTO1-1 is a new target for regulating cytokines IL-1β and IL-18 related to NLRP3 inflammasomes through small molecular inhibitors, in some cases anti-inflammatory drugs targeting these cytokines may increase the risk of CRC occurrence [21].